Collaborative cancer research agreement
The National Cancer Center, situated in Chuo-ku, Tokyo, Japan, and Shimadzu have reached a comprehensive collaborative research agreement that, it is hoped, will lead to the development of internationally leading, high-level, cutting-edge medical technologies that contribute to the suppression of cancer and the promotion of human health.
The National Cancer Center, situated in Chuo-ku, Tokyo, Japan, and Shimadzu have reached a comprehensive collaborative research agreement that, it is hoped, will lead to the development of internationally leading, high-level, cutting-edge medical technologies that contribute to the suppression of cancer and the promotion of human health. These include technological developments related to the realization of ultra-early cancer diagnoses, pharmacokinetic analysis for the achievement of a revolution in the drug discovery process, and medical treatments. According to the company, these developments will be accomplished through a fusion of the high-level cancer research techniques and clinical experience at the centre, and the company’s technologies in next-generation medical treatment fields.
The company has been pursuing R&D in the medical treatment fields of molecular imaging technology and biomarker searches, based on the fusion and application of its chromatography, mass spectrometry and other core analysis and measuring technology with medical imaging technology.
“Thus far,” said the company’s president Akira Nakamoto, ”the life sciences have been the core enterprise at Shimadzu. In the future, however, I would like to see the biomarker candidates discovered to‑date applied to ultra-early diagnosis; we believe this can be accomplished through the implementation of clinically useful medical science and a fusion of imaging diagnostics and molecular imaging, in conjunction with the NCC.”
For more information on the company visit www.shimadzu.com
This story originally appeared in The Column. Click here to view that issue.
AI and GenAI Applications to Help Optimize Purification and Yield of Antibodies From Plasma
October 31st 2024Deriving antibodies from plasma products involves several steps, typically starting from the collection of plasma and ending with the purification of the desired antibodies. These are: plasma collection; plasma pooling; fractionation; antibody purification; concentration and formulation; quality control; and packaging and storage. This process results in a purified antibody product that can be used for therapeutic purposes, diagnostic tests, or research. Each step is critical to ensure the safety, efficacy, and quality of the final product. Applications of AI/GenAI in many of these steps can significantly help in the optimization of purification and yield of the desired antibodies. Some specific use-cases are: selecting and optimizing plasma units for optimized plasma pooling; GenAI solution for enterprise search on internal knowledge portal; analysing and optimizing production batch profitability, inventory, yields; monitoring production batch key performance indicators for outlier identification; monitoring production equipment to predict maintenance events; and reducing quality control laboratory testing turnaround time.
2024 EAS Awardees Showcase Innovative Research in Analytical Science
November 20th 2024Scientists from the Massachusetts Institute of Technology, the University of Washington, and other leading institutions took the stage at the Eastern Analytical Symposium to accept awards and share insights into their research.
